<DOC>
	<DOCNO>NCT02259855</DOCNO>
	<brief_summary>The primary objective : - To determine effect steady state TPV co-administered low dose RTV steady state PegIFN RBV HIV negative subject mild hepatic impairment ( scheme A ) - To determine effect steady state pegylated interferon ( PegIFN ) RBV steady state pharmacokinetics TPV co-administered low dose RTV HIV negative subject mild hepatic impairment ( scheme A ) - To determine pharmacokinetics single dose steady state TPV/r 500/200 mg subject moderate hepatic insufficiency ( scheme B )</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Tipranavir/Ritonavir , Ribavirin , Pegylated Interferon ( Peg INF ) Hepatitis C ( HCV ) Subjects With Mild Hepatic Impairment HCV , Hepatitis B ( HBV ) , Hepatitis D Infected Subjects Alcoholic Cirrhosis With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Liver Cirrhosis , Alcoholic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Age ≥18 Age ≤ 75 year BMI ≥18 BMI ≤ 29 kg/m2 ( Body Mass Index ) screen visit Signed date write informed consent prior admission study accordance good clinical practice ( GCP ) local legislation Ability swallow multiple large capsule without difficulty Serologic evidence chronic hepatitis C infection antibody test HCV branch DNA ( bDNA ) subject mild hepatic impairment ( Scheme A ) Serologic evidence chronic hepatitis C , B and/or delta infection antibody test HCV bDNA , HBV RNA polymerase chain reaction ( PCR ) subject moderate hepatic impairment ( Child Pugh B ) Alcoholic cirrhosis , subject moderate hepatic impairment ( Child Pugh B ) . Patients stop alcohol consumption least 1 month screen without evidence acute alcoholic hepatitis Subjects HCV positive mild hepatic insufficiency stable treatment PegIFN ribavirin since least 12 week prior study entry Subjects mild hepatic insufficiency viral nonresponders less 2 log reduction HCV RNA , compare baseline ( HCV treatment initiation ) positive HCV RNA 12 week therapy PegIFN/RBV Subjects : stable mild hepatic insufficiency treat PegIFN RBV moderate hepatic insufficiency [ ChildPugh Class B ( score 79 ) ] All fertile male female , respective partner ( ) use two form effective contraception ribavirin treatment 6 month end . All woman must agree use effective form contraception entire duration study . This may include condom , diaphragms implant . This apply surgically sterilize post menopausal state Laboratory value indicate adequate baseline organ function require time screen . All subject mild moderate hepatic insufficiency laboratory value less equal grade 2 , base division aid ( DAIDS ) Grading Scale . The following exception make : Alanine transaminase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal ( ULN ) Alkaline Phosphatase &lt; 2 x ULN Haemoglobin &gt; 10.0 g/dL Platelets &gt; 50.000 / μl And healthy control subject laboratory value &lt; grade 1 Willingness abstain alcohol start 2 day prior administration study drug end study , abstain counter herbal medication duration trial Willingness abstain follow start 14 day prior administration study medication end study : Grapefruit grapefruit juice , red wine , seville orange ( marmalade ) , St John 's Wort Milk Thistle Willingness abstain follow 72 h prior PK sampling : Garlic supplement , Methylxanthine contain drink ( coffee , tea , cola , energy drink , chocolate , etc . ) Acceptable medical history , physical examination require prior enter treatment phase trial Reasonable probability completion study , include dosing requirement TPV/r acceptance risk hepatic decompensation Use medication list protocol within 30 day prior Day 1 Participation another trial investigational medicine within 2 month prior Day 1 Absolute neutrophil count ( ANC ) &lt; 750 cells/mm³ screen Serum creatine level &gt; 1.5 time upper limit normal screen History acute illness within 60 day prior Day 1 Subject mild hepatic impairment ( scheme A ) , HIV , HBV , hepatitis Delta positive and/or alcoholic cirrhosis Subject moderate hepatic impairment ( CPB ) , HIV positive Subject control , HIV hepatitis positive alcoholic cirrhosis Subjects HIV positive , HBV positive , subject control HCV positive Active bleeding oesophageal varix condition consistent active decompensated liver disease , active spontaneous bacterial peritonitis , active oesophageal variceal disease active liver encephalopathy Subjects ChildPugh Class C ( score &gt; 9 ) Alcohol abuse within 1 month prior screen study Other substance abuse within 6 month prior screen study Subjects history illness allergy ( include drug allergy ) , opinion investigator , might confound result study pose additional risk administer TPV RTV Subjects take ( within 7 day prior Day 1 ) overthecounter prescription medication , opinion investigator consultation Boehringer Ingelheim France ( BIF ) clinical monitor , might interfere absorption , distribution , metabolism study medication Known hypersensitivity sulphonamide class drug Known hypersensitivity TPV , RTV antiretroviral drug ( market experimental use part clinical research study ) Known elevate liver enzyme past clinical trial compound Inability adhere protocol Cautions warning RTV , PegIFN RBV package insert , opinion investigator , constitute ground subject exclusion History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable trial History systemic antineoplasic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) ≤ 6 month prior study entry expectation treatment would need time study Use hormone replacement therapy oestrogenbased preparation least 1 month prior screen duration study Administration antimicrobial agent within 10 day prior Day 1 ( Visit 2 ) Subjects evidence hepatocellular carcinoma , test positive serum alpha foeto protein &gt; 5μg/l suspect tumour base ultrasonography examination , Patients history stroke , intracranial aneurysm , neurosurgery skull traumatism within 4 week prior screen History intracranial , intraocular , spinal , retroperitoneal atraumatic intraarticular bleed Gastrointestinal hemorrhage within past year Endoscopically document gastroduodenal ulcer disease previous 30 day Hemorrhagic disorder bleed diathesis Need anticoagulant treatment disorder Uncontrolled hypertension ( systolic blood pressure ( SBP ) &gt; 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; 100 mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>